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Abstract
Background: Fever is a common symptom in the emergency department(ED). Fever can be caused by bacterial
infections, which are treated with antibiotics. Often, bacterial infections cannot be ruled out in the ED using standard
diagnostics, and empiric antibiotic treatment is started. Procalcitonin(PCT) is a biomarker for bacterial infections, but its
role in an undifferentiated ED population remains unclear. We hypothesize that PCT-guided therapy may reduce
antibiotics prescription in undifferentiated febrile ED patients. The primary objectives of this study are to determine a)
the efficacy, b) the safety of PCT-guided therapy, and c) the accuracy of the biomarker PCT for bacterial infections. The
secondary objective is to study the cost-effectiveness of PCT-guided therapy.
Methods/design: This is a multicenter noninferiority randomized controlled trial. All adult ED patients with
fever(≥38.2 °C) are randomized between standard care with and without the addition of a PCT level, after written
informed consent.
a) For efficacy, the reduction of patients receiving antibiotics is calculated, using a superiority analysis: differences
between the PCT-guided group and control group are assessed using a Fisher’s exact test, and a multivariable
logistic regression analysis to account for the effects of demographic and medical variables on the percentage of
febrile patients receiving antibiotics.
b) Safety consists of a composite endpoint, defined as mortality, intensive care admission and ED return visit within
14 days. Noninferiority of PCT will be tested using a one-sided 95 % confidence interval for the difference in the
composite safety endpoint between the PCT-guided and control groups using a noninferiority margin of 7.5 %.
c) Accuracy of PCT and CRP for the diagnosis of bacterial infections will be reported, using the sensitivity, specificity,
and the area under the receiver-operating-characteristic curve in the definitive diagnosis of bacterial infections.
The sample size is 550 patients, which was calculated using a power analysis for all primary objectives. Enrollment of
patients started in August 2014 and will last 2 years.
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Discussion: PCT may offer a more tailor-made treatment to the individual ED patient with fever. Prospective
costs analyses will reveal the economic consequences of implementing PCT-guided therapy in the ED.
This trial is registered in the Dutch trial register: NTR4949
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Background
Fever is one of the most common symptoms of patients
visiting the emergency department (ED). The etiology of
fever is diverse, ranging from infectious diseases to neo-
plasms and trauma [1]. Specific etiologies of fever, such
as severe bacterial infections, have to be treated within
one hour after ED presentation with adequate antibiotic
therapy, according to the surviving sepsis guidelines [2].
Because time is of the essence in the initiation of ther-
apy, physicians in the ED have a limited time window
for diagnosing the etiology of fever. This results in a
“better safe than sorry” approach, in which broad-
spectrum antibiotics are administered to febrile patients,
only based on history and physical examination, and
readily available diagnostic entities.
On the other hand, antibiotic resistance is becoming
an increasing problem worldwide. Antimicrobial stew-
ardship advocates thoughtful initiation of antibiotic ther-
apy. Thus, in treatment of bacterial infections, both
under-treatment and overtreatment are undesirable.
Therefore, it is vital to increase the accuracy of diagnos-
tics of febrile illness.
The mainstay of diagnosing the etiology of fever in the
ED consists of history, physical examination and labora-
tory analysis of serum and other bodily fluids, and chest
X-ray examinations. Cultures and viral throat swabs are
obtained, but are of no use in the ED, because results
take several hours to days and treatment has to be
started early after ED presentation [2]. Currently,
leukocyte count, with or without leukocyte differenti-
ation, and C-reactive protein (CRP) are the laboratory
discriminators of choice in the initial approach in the
diagnostic process of febrile diseases.
A higher accuracy of ruling in or ruling out bacterial
infections using biomarkers may result in more accurate
antimicrobial therapy. On the individual patient level,
fewer patients would be treated empirically with antibi-
otics. Adverse events and drug interactions would be re-
duced. Also, a more accurate diagnosis could save
hospital expenses and result in cost reductions. On a
population level, antibiotics resistance could be coun-
tered. For patient safety, this should obviously be with-
out an added risk of under-treatment.
Procalcitonin (PCT) is a promising biomarker for bac-
terial infections. PCT is a precursor protein of calci-
tonin. Unlike calcitonin, which is only produced in the
C-cells of the thyroid gland, PCT can be produced ubi-
quitously throughout the human body. The production
of PCT is upregulated by proinflammatory cytokines like
interleukin -1 (IL-1), IL-2, IL-6 and tumor necrosis fac-
tor alpha, and directly by bacterial endotoxins and lipo-
polysaccharide. Interferon gamma, a cytokine associated
with viral infections, reduces the upregulation of PCT. It
has been shown that PCT levels in non-infectious febrile
conditions, such as autoimmune diseases or fever caused
by malignant disorders stay low, whereas CRP levels
often rise significantly [3]. Furthermore, an increase in
PCT levels can be monitored within 4 to 6 h after start
of infection [4–6]. In comparison, CRP is an acute phase
protein synthesized exclusively in the liver. CRP levels
increase during inflammatory states, but are not specific
for bacterial infections and take more time, 6 to 48 h
after start of infection, to be detectable compared to
PCT [5, 7]. These characteristics give PCT a theoretical
advantage over CRP.
Recently, clinical studies have focused on PCT as a
biomarker of bacterial infections, showing better diag-
nostic properties than commonly used markers such as
CRP [3, 8–14]. Studies have shown that PCT-guided
antibiotic therapy- i.e. starting or withholding antibi-
otics, based on the PCT-level - is safe and reduces
prescription of antibiotics in several distinct patient
groups: savings of more than 23 % in the intensive care
unit (ICU) and up to 78 % in the general practice setting
[8, 11, 15]. However, evidence of the effectiveness of
PCT-guided antibiotic therapy in an undifferentiated ED
population is scarce.
The ED is the gateway of hospital healthcare. Patients
enter with symptoms and leave with a diagnosis. Either
they are admitted, or are sent home. For almost every
diagnosis, there are numerous medical tests and inter-
ventions available that can be utilized in the ED. How-
ever, budgets are limited and should therefore be used in
the most efficient manner possible. ED based cost-
effectiveness studies are used to estimate the value for
money offered by new technologies. These studies serve
as a tool for hospital administrators and decision makers
who are responsible for prioritizing interventions under
economic constraints [16].
Estimated yearly costs associated with antibiotic resist-
ance in Europe are in the range of 1.5 billion euros,
comprising extra healthcare costs and productivity losses
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caused by infections due to antibiotic-resistant bacteria
[17]. PCT-guided therapy may contribute to a reduction
of these enormous costs. It may lead to a reduction in
costs of antibiotics and additional diagnostics tests, such
as blood cultures in non-bacterial disease. Costs of hos-
pital admissions could be reduced as admission for ob-
servation may become obsolete. As an added effect,
there may be a reduction of productivity losses, related
to paid and unpaid work. Patients may be able to return
to their daily activities faster.
The current evidence on the cost-effectiveness of PCT-
guided therapy consists of retrospective hypothetical
models. One study analyzed the cost-effectiveness of PCT
testing in patients hospitalized for community-acquired
pneumonia with a mathematical model [18]. The authors
showed that a PCT-guided protocol would cost less and
would be more effective than usual care [18]. Recently, a
model-based study from the US assessed the economic
impact of PCT testing in patients with acute respiratory
tract infections. The authors documented that PCT-
guided care was cost saving in inpatient, ICU and out-
patient settings, mainly due to a reduction in antibiotic
costs. Total yearly savings at the US national level were
calculated at 1.6 billion dollars [19].
These estimates only included costs of PCT testing
and savings on costs of hospitalization, excluding savings
from other care consumption and productivity losses,
which cannot be estimated at this stage. There is a need
to broaden the evidence base to promote the efficient
use of PCT-guided therapy in patients with fever pre-
senting at EDs.
The primary objectives of this study are to determine
a) the efficacy and b) the safety of PCT-guided therapy,
and c) the accuracy of the biomarker PCT for bacterial
infections. The secondary objective is to study the cost-
effectiveness of PCT-guided therapy.
Methods and design
The HiTEMP study is designed as a multicenter noninfe-
riority randomized controlled trial on PCT-guided ther-
apy. The study will be performed in both academic and
non-academic teaching hospital settings. Patients will be
asked for written informed consent. Patients who consent
are randomized using an online computer program, to ei-
ther the standard-of-care diagnostic workup of febrile pa-
tients (control group), or the standard-of-care workup
with the addition of the diagnostic biomarker PCT.
Outcome measures
Primary outcome measures
a) The efficacy of PCT-guided therapy is defined as the
percentage of patients who are prescribed antibiotics
in the ED.
b) The safety outcome measure consists of a composite
endpoint of 30 days mortality, intensive care unit
(ICU) admission within 30 days, or a return visit to
the ED within 14 days.
c) The accuracy of the definitive diagnosis is reported
for PCT and CRP using the sensitivity, specificity,
and the AUC of the diagnosis of bacterial infections.
The definitive diagnosis is defined in two ways. 1. As
“confirmed bacterial infection”, in which culture –
and PCR results that fit the clinical case
presentation are used to report presence of bacterial
infections. 2. As “suspected bacterial infection”, in
which two independent physicians will give their
expert opinion on the presence of a bacterial
infection using culture results, image modalities and
clinical course, in case of discrepancy, a third
physician will decide.
Secondary outcome measures
Secondary outcome measures for cost-effectiveness are
hospital treatment costs, related medical consumption
during follow-up, costs of absenteeism and reduced
productivity while at work.
The adherence to PCT advice is reported, including
the percentage of antibiotic prescriptions with low PCT
result, and withholding of antibiotics in patients with
high PCT result.
The percentage of patients who received antibiotics
without suspected bacterial infection is reported.
Outcome measures are reported for the total patient
population, and are stratified by source of infection: re-
spiratory tract infections, urinary tract infections, skin
and soft tissue infections, central nervous system infec-
tions, abdominal infections, non-infectious fever, fever
without source, and other causes of fever.
Inclusion and exclusion criteria
Inclusion criteria: All patients of 18 years and older visit-
ing the ED, with a temperature of ≥ 38.2 °C (100.8 °F)
are eligible. Temperature is measured using an ear
thermometer, in triage. Eligible patients need to provide
written informed consent.
Exclusion criteria: Patients with specific immunocom-
promised status, defined as neutropenia with absolute
neutrophil count less than 0.5×109/L, current chemo-
therapy, or post-organ transplantation are excluded. Fur-
thermore, pregnant patients, moribund patients and
patients with a diagnosis that requires primary surgical
intervention, or within 72 h after surgery are excluded.
Patients are randomized using a minimization procedure
[20]. The factors for minimization are imbalance in
randomization result and study site. The randomization
result is allocated at patient enrolment by a computer
generated algorithm.
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Sample size calculation and statistical analyses
Sample size and power analysis: For the three primary
objectives the following analyses are used: a) a superior-
ity analysis for the reduction in the percentage of febrile
patients receiving antibiotics. b) a noninferiority analysis
for safety, and c) an analysis of the test characteristics
(sensitivity and specificity) of the biomarker PCT and
CRP. The total sample size calculation is based on a
power analysis for each of these three primary outcome
measures; the total sample size is the maximum of the
required sample sizes for the different primary outcome
measures.
a) For the superiority analysis of the reduction in the
prescription of antibiotics, we assumed that
antibiotics are initially prescribed at the ED to 73 %
of the patients in the control arm, and that the
intervention will reduce this percentage to 53 %,
based on a careful estimate using recent literature
[14]. To obtain 80 % power to detect a significant
difference between the two groups using a two-sided
Fisher’s exact test with a significance level of 5 %,
the required sample size is 101 patients per group.
b) The noninferiority analysis for the safety objective
uses a composite endpoint consisting of ICU
admittance, 30-days mortality or second ED visit
within 14 days. For an accurate sample size calcula-
tion, we first analyzed ED data from the Erasmus
MC from January 2011 until May 2012. In this data
set, the prevalence of the composite safety endpoint
was 12.7 % (102 cases out of 809 patients). We used
this percentage as the expected rate in the control
group. Using a noninferiority margin of 7.5 %, a
noninferiority analysis comparing the rates in the
control and the intervention groups requires 244
patients in each group to obtain 80 % power with a
one-sided alpha of 5 %. To account for 10 % ex-
pected dropout, the total sample size must be 550
patients.
c) The third sample size calculation is based on a
comparison of sensitivity and specificity of PCT and
CRP in patients with infection. We used data from a
meta-analysis [21, 22] to estimate the accuracy of
PCT and CRP for bacterial infection. We conserva-
tively assumed zero correlation between the test re-
sults of PCT and CRP for the diagnosis of bacterial
infection. For the prevalence of bacterial infections,
we used data from our pilot study [3] to obtain a
representative estimate of the prevalence of bacterial
infections, which led to an estimated prevalence of
68 %. Based on the results of the meta-analysis, the
sensitivity of PCT was 0.83 and for CRP 0.73; the
specificity was 0.88 for PCT and 0.60 for CRP. Using
McNemar’s test, 340 patients with a bacterial
infection (340/0.68 = 500 patients in total) are re-
quired to obtain 80 % power for detecting a differ-
ence in sensitivity between PCT and CRP. Forty-one
patients without a bacterial infection (41/(1–0.68) =
129 patients in total) are required to obtain 80 %
power for detecting a difference in specificity be-
tween PCT and CRP. To ensure sufficient power for
all three primary outcome measures, we thus use a
sample size of 275 patients per group (550 patients
in total).
Statistical analyses for the primary study parameters:
a) Antibiotics use. The percentage of patients that are
prescribed antibiotics is compared between the
PCT-guided group and control group using a Fish-
er’s exact test. Demographic parameters (age, sex,
mortality), medical parameters (medication use, co-
morbidity, temperature, CRP and PCT measure-
ments), hospital admission related parameters
(hospital admittance, hospital length of stay, ICU ad-
mittance, ICU length of stay) are compared between
the PCT-guided group and control group using Fish-
er’s exact tests for dichotomous variables, chi-square
tests for categorical variables with more than two
categories, t-tests for continuous variables that are
normally distributed, and Kruskal-Wallis tests for
continuous variables that are not normally distrib-
uted. A logistic regression analysis will be used to
determine the influence of these parameters on the
proportion of antibiotics prescriptions in the control
group and the PCT-guided therapy group. To select
the independent variables in this logistic regression
model, we will use a stepwise backward approach in
which only the independent variables are retained
that have a significant effect using a significance
level of 5 %; however, the variable group (PCT-
guided group versus control group) will be included
in the model irrespective of the results. In the event
of missing values in possible confounding data, like
intoxications and prescription drugs use, we will use
multiple imputation. Both an intention to treat ana-
lysis and a per protocol analysis will be performed.
Physician adherence to the PCT guidance will be
determined.
b) Safety. Significant differences between the PCT-
guided group and control group in the composite
safety endpoint are determined using a one-sided
upper 95 % confidence limit for the difference in
proportion between the PCT-guided group and the
control group. This confidence interval will be cal-
culated using the method of Agresti and Caffo [23].
Noninferiority of the intervention will be established
if the 95 % confidence interval excludes 7.5 %, i.e. if
van der Does et al. BMC Emergency Medicine  (2016) 16:17 Page 4 of 7
PCT-guided prescription of antibiotics does not in-
crease the rate of the composite endpoint by more
than 7.5 percentage points. Differences in hospital
length of stay will be assessed using the Kruskal-
Wallis test.
c) Accuracy of PCT and CRP. In all patients, the final
diagnosis of the etiology of fever will be determined.
Also, it will be determined if there is a bacterial
infection. The variables “confirmed bacterial
infection” and “suspected bacterial infection” will
serve as gold standards for the evaluation of the
accuracy of the biomarkers CRP and PCT. These
will be determined retrospectively, using culture
results and all diagnostic tests available. In all
patients, both PCT and CRP levels will be available
for statistical analysis. The ability to predict bacterial
infection of both PCT and CRP will be evaluated
using receiver operating characteristic curves, and
the area under the curve will be calculated. In
addition, logistic regression will be performed to
analyze the effects of PCT and CRP levels on the
probability of a bacterial infection. The independent
variables in this analysis are age, sex, PCT, CRP,
temperature, comorbidity, and other variables that
have a p < 0.1 for the difference between groups. We
will account for possible non-linear effects of age,
PCT, CRP and temperature by using appropriate
transformations of these variables.
Statistical analyses for the secondary study
parameters
The study will involve an economic evaluation from
the societal perspective comparing PCT-guided ther-
apy with usual care. The economic evaluation will use
the technique of cost-minimization analysis, which
compares two interventions of identical effectiveness
to find out which is less costly. Total treatment costs
will be compared between the PCT-guided therapy
arm and the control arm, including costs for PCT
testing (intervention group only), other diagnostic
tests, ED visits, antibiotics and other medications, ad-
verse effects of antibiotics, hospital admissions, return
visits to the general practitioner (GP) and other re-
lated medical consumption. These costs will be taken
into account during the one-month follow-up period.
Unit prices will be calculated using real economic
cost prices or using standard cost-prices for health
economic evaluations [24].
Unit prices will be multiplied by the quantities for
each resource used, and then summed over the separate
types of resource to give a total cost per patient. In
addition, differences in labor productivity losses will be
evaluated by comparing costs of absence from work (ab-
senteeism) and reduced productivity while at work
(presenteeism). Moreover, productivity losses related to
unpaid work (e.g., household work, shopping, odd jobs,
and voluntary work) will be included. Productivity losses
will be evaluated using the Productivity Costs Question-
naire [25]. Mean total costs will be calculated for pa-
tients in each treatment group.
Laboratory examinations
Blood samples will be obtained at inclusion. Samples will
be centrifuged (3000 N Relative centrifugal force (Rcf ) at
room temperature for 5 min). The serum will be mea-
sured on the routine analyzer of the clinical chemistry
laboratory (Roche Cobas 8000 system, Roche Diagnos-
tics Netherlands). PCT-measurements will be performed
by using an electro-chemiluminiscent immunoassay
(ECLIA) (Roche diagnostics, Brahms, Henningsdorf,
Germany). All samples will be measured and reported
without knowledge of the clinical status of the subjects.
PCT-guided therapy
PCT-guided therapy is defined as the initiation of antibi-
otics, based on all available diagnostics with the addition
of PCT-levels. The PCT results are appraised using a
two-point scale, in which bacterial infections are respect-
ively deemed unlikely (PCT < 0.5 μg/L) and likely (PCT ≥
0.5 μg/L). These cut-off values are used in other trials
[26–28].
Follow-up
One month after inclusion, patients will be contacted by
telephone by one of the investigators. Course of the dis-
ease, including medicine use, related GP hospital visits
(and diagnostics/prescriptions), and labor productivity
losses, will be evaluated. Three months after inclusion,
one of the investigators will contact patient’s GP in order
to evaluate the final outcome of the febrile episode. Pa-
tients are allowed to participate only once.
Adverse events
The composite safety endpoint is continually monitored
during the trial. Also, adverse events, not in the compos-
ite safety endpoint - death after 30 days, life threatening
events or any other important medical event that may
jeopardize patients in any way - are monitored by the
data safety monitoring board of the study.
Ethics approval and trial registration
The ethics committee of the Erasmus University Medical
Center, in Rotterdam, the Netherlands, approved this trial.
It is conducted according to the principles of the Declar-
ation of Helsinki, version March 1, 2013 and in accord-
ance with the Dutch Medical Research Involving Human
Subjects Act (Wet Medisch wetenschappelijk Onderzoek
met mensen, WMO). The CONSORT statements and its
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revised extension for reporting noninferiority trials were
consulted and taken into account when designing and
writing this protocol [29, 30]. The trial has been registered
in the Dutch trial registry, NTR4949.
Discussion
Although observational studies have shown that PCT is
more sensitive and specific for bacterial infections in
comparison to CRP [14, 31], and prospective trials have
investigated the reduction of antibiotics in patients with
respiratory complaints [32, 33], the role of PCT in the
ED remains unclear. This study is designed to answer
the question whether PCT can aid in improving the ac-
curacy of diagnosing bacterial infections in an ED set-
ting. The real-life clinical ED setting differs from a
research setting in which patients have very specific
symptoms. Consequently, the value of PCT for ED
patients without specific complaints has not been
determined.
Because of this clinical problem, we used an objective
measurement of temperature of 38.2 °C or higher as sole
inclusion criterion. As a result, we have a more hetero-
geneous population compared to other trials [32, 33],
allowing us to extrapolate the results to the majority of
the adult ED patient population. Furthermore, we will be
able to identify cases where physicians disregard the
PCT level, and investigate the causes. These are urgent
questions in emergency medicine.
The costs of PCT-guided therapy may be of influence
in implementation in clinical practice. In the
Netherlands alone, 94.2 billion euros was spent on
healthcare in 2013, and the costs are rising [34]. There-
fore, there is much interest in healthcare initiatives that
benefit patients’ health and are not associated with
additional costs. Currently, there are no prospective
cost-effectiveness studies on PCT-guided therapy. Two
economic evaluation studies [18, 19] report that a PCT-
guided antibiotic algorithm may reduce costs. However,
physician adherence to the PCT-guided therapy protocol
could not be accurately estimated, and productivity
losses are not analyzed. Therefore, these studies do not
provide concrete evidence. In the HiTEMP study, costs
are analyzed prospectively to provide a more accurate
recommendation.
To reduce the risk of harming patients who receive
PCT-guided therapy, we designed a noninferiority study
protocol for the primary safety objective. Our study is in
its design largely similar to the ProHOSP trial [33]. This
ED based noninferiority trial, which investigates the start
of antibiotic therapy using PCT in patients with sus-
pected respiratory tract infections, uses a composite
endpoint with a noninferiority margin of 7.5 %. More-
over, in the Cochrane review on PCT-guided therapy, no
differences in mortality or treatment failure were found
[35]. We therefore consider the noninferiority margin of
7.5 % of the composite endpoint ethically acceptable.
We use a composite endpoint, consisting of patient cen-
tered outcomes. These outcomes, i.e. mortality, ICU ad-
mittance <30 days or return to ED within two weeks, are
a potential sign of treatment failure.
There are logistical issues that may arise during the
course of the study. One of the most important issues
may be physician protocol adherence. Physicians need to
learn how they should interpret the value of the PCT
level, and develop a certain clinical’feel’ towards it. The
investigators will facilitate adoption of PCT, by inform-
ing every physician prior and during the study. Possibly,
a ‘learning curve’ can be seen in the treatment according
to PCT guidance. However, the physician motivates
every choice of treatment that is not in accordance with
the treatment advice based on the PCT result. Moreover,
the accuracy of PCT will be calculated using the defini-
tive diagnosis. Physician adherence to PCT guidance will
also be investigated.
Conclusions
The HiTEMP trial addresses critical clinical questions in
emergency medicine. PCT may offer a more tailor-made
treatment to the individual ED patient with fever. The
study will also shed light on the cost consequences of
implementing PCT-guided therapy in the ED.
Prospective
The HiTEMP study is open for inclusion. Results are ex-
pected at the end of 2016.
Ethics approval and consent to participate
This study protocol is approved by the medical ethics
committee (Medisch ethische toetsingscommissie,
METC) of the Erasmus University Medical Center, in
Rotterdam, the Netherlands. Reference number MEC
2013–149.
This protocol does not include patient data, therefore
informed consent is not applicable.
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